PETVIVO HOLDING, INC. ANNOUNCES DISTRIBUTION AGREEMENT WITH EQ ESPECIALIDADES
Rhea-AI Summary
PetVivo Holdings (OTCQB: PETV) has signed a distribution agreement with Eq Especialidades to market and distribute Spryng™ with OsteoCushion™ technology throughout Mexico, effective April 1, 2025.
Spryng™ is an intra-articular injectable veterinary medical device containing sterilized, extra-cellular matrix microparticles. The technology works by adsorbing onto animal joint synovial lining and integrating with subsynovial tissue, helping restore proper joint mechanics. It aids in managing noninfectious joint pain conditions including joint instability, degenerative joint disease, and osteoarthritis.
This strategic partnership aims to expand PetVivo's presence in the Mexican animal health market, targeting both equine and companion animal segments.
Positive
- Geographic expansion into Mexican market through established distributor
- Enhanced market access for Spryng™ product line
- Strategic partnership to increase product exposure and market penetration
Negative
- None.
MINNEAPOLIS, April 16, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW) ("PetVivo"), an emerging biomedical device company focused on the commercialization of innovative medical devices and other therapeutics for equine and companion animals, announced today it has entered into a definitive distribution agreement with Eq Especialidades (“Eq Especialidades”). Eq Especialidades will inventory, market and promote PetVivo’s veterinary medical device, Spryng™ with OsteoCushion™ technology, throughout Mexico. Eq Especialidades sales and marketing activities will commence on April 1, 2025.
SPRYNG® with OsteoCushion® Technology, is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
"We are incredibly pleased to add Eq Especialidades to our current distribution network to assist us in commercializing our signature product, Spryng with OsteoCushion technology, in Mexico. By adding Eq Especialidades to our current distribution network, they will assist PetVivo in achieving significant exposure to and penetration in the Mexican animal health market. We believe this new relationship will benefit the veterinary industry, the veterinarians who provide medical care to their patients, the animals receiving Spryng as well as the owners benefiting from the enhanced medical outcomes of their horses and companion animals," stated John Lai, Chief Executive Officer for PetVivo Holdings, Inc.
”For more information about PetVivo Holdings, Inc. please contact info1@petvivo.com or visit https://petvivo.com/ and https://www.sprynghealth.com.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCQB: PETV; OTCPINK: PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead products SPRYNG™ with OsteoCushion™ technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale.
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
Forward-Looking Statements:
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
FAQ
What is the new distribution agreement announced by PETV for Mexico?
How does PETV's Spryng™ technology work for joint treatment?
What medical conditions does PETV's Spryng™ treat in animals?
When will PETV's distribution partnership with Eq Especialidades begin operations?
